Indrayani Biotech Limited (IBL) clocked a strong growth trajectory in FY23 with consolidated revenues of Rs 167 crore, as compared to revenue of Rs 62 crore in FY22. FY23 turned out to be a transformational year, with revenue growth of 171%. EBITDA margins also showed an upward trend. Indrayani reported…
Read More
Indrayani Biotech (BSE: 526445) is a growth stock that is likely to show strong double digit growth over the next few years. In its Annual Report released the last week, the company has projected a consolidated revenue of Rs 150 crore for FY23. In comparison, the revenue for FY22 was Rs…
Read More